Rockefeller Capital Management L.P. Takes $220,000 Position in REGENXBIO Inc. $RGNX

Rockefeller Capital Management L.P. acquired a new position in REGENXBIO Inc. (NASDAQ:RGNX) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 26,773 shares of the biotechnology company’s stock, valued at approximately $220,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Brooklyn Investment Group lifted its holdings in shares of REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 3,466 shares in the last quarter. Profund Advisors LLC acquired a new position in shares of REGENXBIO during the 2nd quarter worth approximately $106,000. Entropy Technologies LP purchased a new stake in REGENXBIO in the 1st quarter valued at approximately $107,000. Pallas Capital Advisors LLC grew its holdings in REGENXBIO by 67.1% during the 2nd quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 6,992 shares during the last quarter. Finally, Pale Fire Capital SE increased its position in REGENXBIO by 120.5% during the first quarter. Pale Fire Capital SE now owns 25,846 shares of the biotechnology company’s stock worth $185,000 after buying an additional 14,125 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Wall Street Zen upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Monday, November 24th. Chardan Capital restated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, November 20th. Barclays decreased their price target on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of REGENXBIO in a research report on Tuesday, October 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average target price of $28.63.

REGENXBIO Price Performance

NASDAQ RGNX opened at $13.34 on Friday. The company has a market cap of $675.27 million, a P/E ratio of -3.84 and a beta of 1.23. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $13.93. The company has a 50-day moving average of $11.55 and a 200-day moving average of $9.82.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The firm had revenue of $29.73 million during the quarter, compared to the consensus estimate of $24.41 million. As a group, equities research analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

Insider Activity at REGENXBIO

In related news, CEO Curran Simpson sold 20,811 shares of the stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $12.62, for a total value of $262,634.82. Following the transaction, the chief executive officer directly owned 216,162 shares of the company’s stock, valued at approximately $2,727,964.44. This trade represents a 8.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 36,169 shares of company stock worth $416,598. Corporate insiders own 12.79% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.